SPLASH Trial TT

SPLASH Trial TT

Search

SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment - Oliver Sartor Details Oliver Sartor discusses the SPLASH trial results, evaluating Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients who progressed on ARPI therapy. The study shows significant improvement in radiographic progression-free survival for Lutetium-177-PNT2002 compared to alternate ARPI therapy, with a hazard ratio of 0.71. Dr. Sartor highlights the favorable safety profile and...
Efficacy and Safety of 177Lu-PNT2002 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer in the SPLASH - Neil Fleshner Details Charles Ryan is joined by Neil Fleshner to discuss the efficacy and safety of radioligand 177Lu-PNT2002 in PSMA-positive patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after treatment with androgen receptor axis-targeted therapy (ARAT) in the SPLASH trial. Drs. Ryan and Fleshner start by discussing the issue of dosimetry and why it was important for the FDA to...
Clinical Trials in Progress: PSMA-Based Radioligand, 177Lu-PNT2002 For Men With Metastatic Castration-Resistant Prostate Cancer - The SPLASH Study - Neil Fleshner Details Charles Ryan is joined by Neil Fleshner to discuss the multi-center, open-label, phase III SPLASH study evaluating the efficacy of 177Lu-PNT2002, a PSMA-based radioligand, for men with progressive metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor axis-targeted (ARAT) therapy which is underway and accruing in many sites around the world. Biographies: Neil Fleshner, MD,...